Post-treatment urinary sarcosine as a predictor of recurrent
relapses in patients with prostate cancer

J 2018

Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer

GUMULEC, Jaromír, Martina RAUDENSKÁ, Dalibor PACÍK, Mariana PLEVOVÁ, Alena SOROKAČ KUBOLKOVÁ et. al.

Základní údaje

Originální název

Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer

Autoři

GUMULEC, Jaromír (203 Česká republika, domácí), Martina RAUDENSKÁ (203 Česká republika, domácí), Dalibor PACÍK (203 Česká republika, domácí), Mariana PLEVOVÁ (703 Slovensko, domácí), Alena SOROKAČ KUBOLKOVÁ (703 Slovensko, domácí), Zuzana LACKOVÁ (203 Česká republika), Natalia Vladimirovna CERNEI (498 Moldavsko), Vladislav STRMISKA (203 Česká republika), Ondrej ZITKA (203 Česká republika), Zbynek HEGER (203 Česká republika) a Vojtech ADAM (203 Česká republika, garant)

Vydání

Cancer Medicine, Houston, John Wiley & Sons Ltd. 2018, 2045-7634

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.357

Kód RIV

RIV/00216224:14110/18:00104807

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1002/cam4.1767

UT WoS

000450673300009

Klíčová slova anglicky

outcome; prostate cancer; relapse; sarcosine; survival

Štítky

14110225, 14110518, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 2. 2019 17:36, Soňa Böhmová

Anotace

V originále

To date, there has been no evidence regarding the association between urinary sarcosine content and prostate cancer survival. Our main objective was to investigate whether levels of post-treatment urinary sarcosine are associated with relapse. The inclusion criteria were (in accordance with EAU 2017) as follows: histopathologically verified adenocarcinoma in prostate biopsy cores or specimens from transurethral resection of the prostate (TURP) or prostatectomy for benign prostatic enlargement (BPE) with retained ability to urinate. The median follow-up was 53 months. In the study, we retrospectively evaluated a cohort of 511 patients with prostate cancer with various risk factors and treatment strategies. Post-treatment sarcosine levels were elevated in 266 (52%) patients and highly elevated (>= 200 nmol/L) in 71 (13%) patients. Urinary sarcosine content was significantly associated with number of relapses that patients experienced, P = 0.002 for sarcosine >= 200 vs <= 30 nmol/L. Multivariate analysis revealed that sarcosine was an independent predictor of recurrent relapses (>= 2 relapses with an intermediate period of remission), HR = 3.89 (95% CI 1.29-11.7) for sarcosine >200 vs <30 nmol/L. This trend was even more pronounced in a subgroup of patients who underwent radical prostatectomy, HR = 3.29 (95% CI 1.06-10.18), where (single) relapse-free survival could also be predicted by sarcosine levels, HR = 1.96 (1.05-3.66). Urinary sarcosine may become a possible predictor for patients' outcomes, because patients with elevated post-treatment sarcosine could be predicted to have recurrent relapses of the disease.

Návaznosti

ROZV/25/LF/2017, interní kód MU

Název: LF - Příspěvek na IP 2017

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, LF - Příspěvek na IP 2017, Interní rozvojové projekty

Citovat

GUMULEC, Jaromír, Martina RAUDENSKÁ, Dalibor PACÍK, Mariana PLEVOVÁ, Alena SOROKAČ KUBOLKOVÁ, Zuzana LACKOVÁ, Natalia Vladimirovna CERNEI, Vladislav STRMISKA, Ondrej ZITKA, Zbynek HEGER a Vojtech ADAM. Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer. Cancer Medicine. Houston: John Wiley & Sons Ltd., 2018, roč. 7, č. 11, s. 5411-5419. ISSN 2045-7634. Dostupné z: https://dx.doi.org/10.1002/cam4.1767.

@article{1475297,
   author = {Gumulec, Jaromír and Raudenská, Martina and Pacík, Dalibor and Plevová, Mariana and Sorokač Kubolková, Alena and Lacková, Zuzana and Cernei, Natalia Vladimirovna and Strmiska, Vladislav and Zitka, Ondrej and Heger, Zbynek and Adam, Vojtech},
   article_location = {Houston},
   article_number = {11},
   doi = {http://dx.doi.org/10.1002/cam4.1767},
   keywords = {outcome; prostate cancer; relapse; sarcosine; survival},
   language = {eng},
   issn = {2045-7634},
   journal = {Cancer Medicine},
   title = {Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer},
   volume = {7},
   year = {2018}
}

TY  - JOUR
ID  - 1475297
AU  - Gumulec, Jaromír - Raudenská, Martina - Pacík, Dalibor - Plevová, Mariana - Sorokač Kubolková, Alena - Lacková, Zuzana - Cernei, Natalia Vladimirovna - Strmiska, Vladislav - Zitka, Ondrej - Heger, Zbynek - Adam, Vojtech
PY  - 2018
TI  - Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer
JF  - Cancer Medicine
VL  - 7
IS  - 11
SP  - 5411-5419
EP  - 5411-5419
PB  - John Wiley & Sons Ltd.
SN  - 20457634
KW  - outcome
KW  - prostate cancer
KW  - relapse
KW  - sarcosine
KW  - survival
N2  - To date, there has been no evidence regarding the association between urinary sarcosine content and prostate cancer survival. Our main objective was to investigate whether levels of post-treatment urinary sarcosine are associated with relapse. The inclusion criteria were (in accordance with EAU 2017) as follows: histopathologically verified adenocarcinoma in prostate biopsy cores or specimens from transurethral resection of the prostate (TURP) or prostatectomy for benign prostatic enlargement (BPE) with retained ability to urinate. The median follow-up was 53 months. In the study, we retrospectively evaluated a cohort of 511 patients with prostate cancer with various risk factors and treatment strategies. Post-treatment sarcosine levels were elevated in 266 (52%) patients and highly elevated (>= 200 nmol/L) in 71 (13%) patients. Urinary sarcosine content was significantly associated with number of relapses that patients experienced, P = 0.002 for sarcosine >= 200 vs <= 30 nmol/L. Multivariate analysis revealed that sarcosine was an independent predictor of recurrent relapses (>= 2 relapses with an intermediate period of remission), HR = 3.89 (95% CI 1.29-11.7) for sarcosine >200 vs <30 nmol/L. This trend was even more pronounced in a subgroup of patients who underwent radical prostatectomy, HR = 3.29 (95% CI 1.06-10.18), where (single) relapse-free survival could also be predicted by sarcosine levels, HR = 1.96 (1.05-3.66). Urinary sarcosine may become a possible predictor for patients' outcomes, because patients with elevated post-treatment sarcosine could be predicted to have recurrent relapses of the disease.
ER  -

GUMULEC, Jaromír, Martina RAUDENSKÁ, Dalibor PACÍK, Mariana PLEVOVÁ, Alena SOROKAČ KUBOLKOVÁ, Zuzana LACKOVÁ, Natalia Vladimirovna CERNEI, Vladislav STRMISKA, Ondrej ZITKA, Zbynek HEGER a Vojtech ADAM. Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer. \textit{Cancer Medicine}. Houston: John Wiley \&{} Sons Ltd., 2018, roč.~7, č.~11, s.~5411-5419. ISSN~2045-7634. Dostupné z: https://dx.doi.org/10.1002/cam4.1767.

Podrobný výpis o publikaci